Annual CFF
$72.70 M
+$73.10 M+18694.63%
31 December 2023
Summary:
TG Therapeutics annual cash flow from financing activities is currently $72.70 million, with the most recent change of +$73.10 million (+18694.63%) on 31 December 2023. During the last 3 years, it has fallen by -$607.12 million (-89.31%). TGTX annual CFF is now -89.31% below its all-time high of $679.83 million, reached on 31 December 2020.TGTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$134.45 M
+$134.32 M+99495.56%
30 September 2024
Summary:
TG Therapeutics quarterly cash flow from financing activities is currently $134.45 million, with the most recent change of +$134.32 million (+99495.56%) on 30 September 2024. Over the past year, it has increased by +$134.03 million (+31836.82%). TGTX quarterly CFF is now -66.67% below its all-time high of $403.39 million, reached on 31 December 2020.TGTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$134.60 M
+$134.03 M+23722.65%
30 September 2024
Summary:
TG Therapeutics TTM cash flow from financing activities is currently $134.60 million, with the most recent change of +$134.03 million (+23722.65%) on 30 September 2024. Over the past year, it has increased by +$61.84 million (+85.00%). TGTX TTM CFF is now -80.20% below its all-time high of $679.83 million, reached on 31 December 2020.TGTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TGTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | +10000.0% | +85.0% |
| 3 y3 years | -89.3% | +1926.6% | -65.4% |
| 5 y5 years | -36.0% | +549.7% | +21.8% |
TGTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -89.3% | >+9999.0% | at high | +1926.6% | -65.4% | >+9999.0% |
| 5 y | 5 years | -89.3% | >+9999.0% | -66.7% | +1926.6% | -80.2% | >+9999.0% |
| alltime | all time | -89.3% | >+9999.0% | -66.7% | +715.0% | -80.2% | +7034.8% |
TG Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $134.45 M(>+9900.0%) | $134.60 M(>+9900.0%) |
| June 2024 | - | $135.00 K(+1250.0%) | $565.00 K(-98.8%) |
| Mar 2024 | - | $10.00 K(-1100.0%) | $47.48 M(-34.7%) |
| Dec 2023 | $72.70 M(<-9900.0%) | -$1000.00(-100.2%) | $72.70 M(-0.1%) |
| Sept 2023 | - | $421.00 K(-99.1%) | $72.75 M(+0.2%) |
| June 2023 | - | $47.05 M(+86.4%) | $72.61 M(+182.6%) |
| Mar 2023 | - | $25.24 M(>+9900.0%) | $25.70 M(-6672.1%) |
| Dec 2022 | -$391.00 K(-100.9%) | $49.00 K(-82.2%) | -$391.00 K(-100.7%) |
| Sept 2022 | - | $275.00 K(+103.7%) | $55.56 M(+15.9%) |
| June 2022 | - | $135.00 K(-115.9%) | $47.92 M(+18.0%) |
| Mar 2022 | - | -$850.00 K(-101.5%) | $40.62 M(-1.9%) |
| Dec 2021 | $41.42 M(-93.9%) | $56.00 M(-860.7%) | $41.42 M(-89.3%) |
| Sept 2021 | - | -$7.36 M(+2.8%) | $388.81 M(-9.9%) |
| June 2021 | - | -$7.16 M(>+9900.0%) | $431.44 M(-36.5%) |
| Mar 2021 | - | -$55.00 K(-100.0%) | $679.69 M(-0.0%) |
| Dec 2020 | $679.83 M(+232.9%) | $403.39 M(+1043.9%) | $679.83 M(+81.4%) |
| Sept 2020 | - | $35.27 M(-85.4%) | $374.79 M(+4.0%) |
| June 2020 | - | $241.09 M(>+9900.0%) | $360.22 M(+144.4%) |
| Mar 2020 | - | $81.00 K(-99.9%) | $147.41 M(-27.8%) |
| Dec 2019 | $204.21 M(+79.7%) | $98.35 M(+375.3%) | $204.21 M(+84.7%) |
| Sept 2019 | - | $20.70 M(-26.8%) | $110.55 M(+17.2%) |
| June 2019 | - | $28.28 M(-50.3%) | $94.35 M(-20.1%) |
| Mar 2019 | - | $56.88 M(+1111.8%) | $118.09 M(+3.9%) |
| Dec 2018 | $113.64 M(-15.0%) | $4.69 M(+4.5%) | $113.64 M(-8.1%) |
| Sept 2018 | - | $4.49 M(-91.4%) | $123.68 M(-16.1%) |
| June 2018 | - | $52.02 M(-0.8%) | $147.41 M(+48.6%) |
| Mar 2018 | - | $52.43 M(+255.7%) | $99.18 M(-25.8%) |
| Dec 2017 | $133.66 M(+2564.7%) | $14.74 M(-47.8%) | $133.66 M(+11.1%) |
| Sept 2017 | - | $28.22 M(+643.3%) | $120.34 M(+30.6%) |
| June 2017 | - | $3.80 M(-95.6%) | $92.17 M(+0.3%) |
| Mar 2017 | - | $86.91 M(+6016.9%) | $91.91 M(+1732.4%) |
| Dec 2016 | $5.02 M(-92.7%) | $1.42 M(+3085.7%) | $5.02 M(+38.7%) |
| Sept 2016 | - | $44.60 K(-98.7%) | $3.62 M(-81.3%) |
| June 2016 | - | $3.54 M(>+9900.0%) | $19.32 M(-42.2%) |
| Mar 2016 | - | $14.20 K(-34.3%) | $33.41 M(-51.4%) |
| Dec 2015 | $68.72 M(+0.1%) | $21.60 K(-99.9%) | $68.72 M(-28.0%) |
| Sept 2015 | - | $15.74 M(-10.7%) | $95.43 M(-8.1%) |
| June 2015 | - | $17.63 M(-50.1%) | $103.89 M(+20.1%) |
| Mar 2015 | - | $35.33 M(+32.2%) | $86.53 M(+26.1%) |
| Dec 2014 | $68.64 M(+72.9%) | $26.73 M(+10.4%) | $68.64 M(+63.6%) |
| Sept 2014 | - | $24.20 M(+8771.0%) | $41.96 M(-24.6%) |
| June 2014 | - | $272.80 K(-98.4%) | $55.69 M(-0.9%) |
| Mar 2014 | - | $17.44 M(>+9900.0%) | $56.20 M(+41.6%) |
| Dec 2013 | $39.69 M(+233.7%) | $48.40 K(-99.9%) | $39.69 M(+0.3%) |
| Sept 2013 | - | $37.92 M(+4719.8%) | $39.56 M(+2313.4%) |
| June 2013 | - | $786.80 K(-16.0%) | $1.64 M(+105.7%) |
| Mar 2013 | - | $936.90 K(-1208.8%) | $796.90 K(-93.3%) |
| Dec 2012 | $11.90 M(+21.1%) | -$84.50 K(<-9900.0%) | $11.90 M(-45.4%) |
| Sept 2012 | - | $0.00(-100.0%) | $21.78 M(-0.1%) |
| June 2012 | - | -$55.50 K(-100.5%) | $21.81 M(>+9900.0%) |
| Mar 2012 | - | $12.04 M(+22.9%) | $0.00(-100.0%) |
| Dec 2011 | $9.82 M(+413.2%) | $9.79 M(>+9900.0%) | $9.82 M(<-9900.0%) |
| Sept 2011 | - | $30.10 K(-100.1%) | -$25.50 K(-81.6%) |
| June 2011 | - | -$21.86 M(-200.0%) | -$138.90 K(-100.6%) |
| Mar 2011 | - | $21.86 M(<-9900.0%) | $21.69 M(+1033.2%) |
| Dec 2010 | $1.91 M | -$55.60 K(-33.3%) | $1.91 M(-12.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$83.30 K(+163.6%) | $2.19 M(-3.7%) |
| June 2010 | - | -$31.60 K(-101.5%) | $2.27 M(-1.4%) |
| Mar 2010 | - | $2.08 M(+854.1%) | $2.30 M(+132.9%) |
| Dec 2009 | $988.80 K(-74.7%) | $218.50 K(>+9900.0%) | $988.80 K(-43.8%) |
| Sept 2009 | - | $0.00(0.0%) | $1.76 M(-3.6%) |
| June 2009 | - | $0.00(-100.0%) | $1.83 M(-32.9%) |
| Mar 2009 | - | $770.30 K(-22.2%) | $2.72 M(-30.4%) |
| Dec 2008 | $3.91 M(-50.3%) | $990.10 K(+1402.4%) | $3.91 M(+33.9%) |
| Sept 2008 | - | $65.90 K(-92.6%) | $2.92 M(+2.4%) |
| June 2008 | - | $894.50 K(-54.3%) | $2.85 M(+44.7%) |
| Mar 2008 | - | $1.96 M(>+9900.0%) | $1.97 M(-74.9%) |
| Dec 2007 | $7.86 M(<-9900.0%) | $0.00(-100.0%) | $7.86 M(0.0%) |
| Sept 2007 | - | -$2000.00(-114.9%) | $7.86 M(-0.0%) |
| June 2007 | - | $13.40 K(-99.8%) | $7.86 M(+0.2%) |
| Mar 2007 | - | $7.85 M(>+9900.0%) | $7.84 M(<-9900.0%) |
| Dec 2006 | -$15.30 K(-100.1%) | $0.00(0.0%) | -$15.30 K(-202.0%) |
| Sept 2006 | - | $0.00(-100.0%) | $15.00 K(-99.9%) |
| June 2006 | - | -$5100.00(-50.0%) | $11.92 M(+2.6%) |
| Mar 2006 | - | -$10.20 K(-133.7%) | $11.62 M(-0.7%) |
| Dec 2005 | $11.70 M(+245.0%) | $30.30 K(-99.7%) | $11.70 M(+0.3%) |
| Sept 2005 | - | $11.91 M(-3978.2%) | $11.67 M(-4829.7%) |
| June 2005 | - | -$307.00 K(-544.9%) | -$246.70 K(-1651.6%) |
| Mar 2005 | - | $69.00 K(>+9900.0%) | $15.90 K(-99.5%) |
| Dec 2004 | $3.39 M(-62.3%) | $0.00(-100.0%) | $3.39 M(-72.7%) |
| Sept 2004 | - | -$8700.00(-80.4%) | $12.42 M(+0.3%) |
| June 2004 | - | -$44.40 K(-101.3%) | $12.38 M(-0.4%) |
| Mar 2004 | - | $3.44 M(-61.9%) | $12.42 M(+38.2%) |
| Dec 2003 | $8.98 M(+261.3%) | $9.03 M(<-9900.0%) | $8.98 M(+262.1%) |
| Sept 2003 | - | -$51.10 K(<-9900.0%) | $2.48 M(+30.9%) |
| June 2003 | - | $0.00(-100.0%) | $1.89 M(-25.2%) |
| Mar 2003 | - | $7700.00(-99.7%) | $2.53 M(+1.9%) |
| Dec 2002 | $2.49 M(+386.8%) | $2.52 M(-496.0%) | $2.49 M(+30.7%) |
| Sept 2002 | - | -$637.40 K(-199.8%) | $1.90 M(-25.1%) |
| June 2002 | - | $638.80 K(-1746.4%) | $2.54 M(+133.1%) |
| Mar 2002 | - | -$38.80 K(-102.0%) | $1.09 M(+113.3%) |
| Dec 2001 | $510.80 K(-22.8%) | $1.94 M(<-9900.0%) | $510.90 K(-126.3%) |
| Sept 2001 | - | -$400.00(-100.0%) | -$1.94 M(+78.3%) |
| June 2001 | - | -$811.10 K(+31.3%) | -$1.09 M(+292.4%) |
| Mar 2001 | - | -$617.60 K(+20.7%) | -$277.40 K(-142.0%) |
| Dec 2000 | $661.30 K(>+9900.0%) | -$511.80 K(-160.1%) | $661.20 K(-43.6%) |
| Sept 2000 | - | $852.00 K(>+9900.0%) | $1.17 M(+265.4%) |
| June 2000 | - | $0.00(-100.0%) | $321.00 K(0.0%) |
| Mar 2000 | - | $321.00 K(>+9900.0%) | $321.00 K(>+9900.0%) |
| Dec 1999 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 1999 | - | $0.00(0.0%) | $100.00 K(0.0%) |
| June 1999 | - | $0.00(0.0%) | $100.00 K(0.0%) |
| Mar 1999 | - | $0.00(-100.0%) | $100.00 K(0.0%) |
| Dec 1998 | $100.00 K(-99.1%) | $100.00 K(>+9900.0%) | $100.00 K(-200.0%) |
| Sept 1998 | - | $0.00(0.0%) | -$100.00 K(-101.2%) |
| June 1998 | - | $0.00(0.0%) | $8.60 M(-18.9%) |
| Mar 1998 | - | $0.00(-100.0%) | $10.60 M(0.0%) |
| Dec 1997 | $10.60 M(+715.4%) | -$100.00 K(-101.1%) | $10.60 M(-0.9%) |
| Sept 1997 | - | $8.70 M(+335.0%) | $10.70 M(+435.0%) |
| June 1997 | - | $2.00 M(>+9900.0%) | $2.00 M(>+9900.0%) |
| Mar 1997 | - | $0.00 | $0.00 |
| Dec 1996 | $1.30 M | - | - |
FAQ
- What is TG Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for TG Therapeutics?
- What is TG Therapeutics annual CFF year-on-year change?
- What is TG Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for TG Therapeutics?
- What is TG Therapeutics quarterly CFF year-on-year change?
- What is TG Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for TG Therapeutics?
- What is TG Therapeutics TTM CFF year-on-year change?
What is TG Therapeutics annual cash flow from financing activities?
The current annual CFF of TGTX is $72.70 M
What is the all time high annual CFF for TG Therapeutics?
TG Therapeutics all-time high annual cash flow from financing activities is $679.83 M
What is TG Therapeutics annual CFF year-on-year change?
Over the past year, TGTX annual cash flow from financing activities has changed by +$73.10 M (+18694.63%)
What is TG Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of TGTX is $134.45 M
What is the all time high quarterly CFF for TG Therapeutics?
TG Therapeutics all-time high quarterly cash flow from financing activities is $403.39 M
What is TG Therapeutics quarterly CFF year-on-year change?
Over the past year, TGTX quarterly cash flow from financing activities has changed by +$134.03 M (+31836.82%)
What is TG Therapeutics TTM cash flow from financing activities?
The current TTM CFF of TGTX is $134.60 M
What is the all time high TTM CFF for TG Therapeutics?
TG Therapeutics all-time high TTM cash flow from financing activities is $679.83 M
What is TG Therapeutics TTM CFF year-on-year change?
Over the past year, TGTX TTM cash flow from financing activities has changed by +$61.84 M (+85.00%)